R&D Incentives: National Academy Puts Focuses On Reimbursement, Not US FDA

 
• By Michael McCaughan
  
The NAM committee wrote a separate policy guide targeted at CMS as part of a report on matching drug development and disease burden. (Shutterstock)

More from R&D

More from United States